Cargando…

Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review

RATIONALE: Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shu-Yue, Shen, Wen, Peng, Yan-Mei, Cui, Hui-Juan, Duan, Hua, Qiu, Yu-Qin, Li, Qiang, Zhang, Jing-Yi, Sun, Chen-Yao, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/
https://www.ncbi.nlm.nih.gov/pubmed/30508887
http://dx.doi.org/10.1097/MD.0000000000013088
_version_ 1783379136568360960
author Zheng, Shu-Yue
Shen, Wen
Peng, Yan-Mei
Cui, Hui-Juan
Duan, Hua
Qiu, Yu-Qin
Li, Qiang
Zhang, Jing-Yi
Sun, Chen-Yao
Zhang, Xu
author_facet Zheng, Shu-Yue
Shen, Wen
Peng, Yan-Mei
Cui, Hui-Juan
Duan, Hua
Qiu, Yu-Qin
Li, Qiang
Zhang, Jing-Yi
Sun, Chen-Yao
Zhang, Xu
author_sort Zheng, Shu-Yue
collection PubMed
description RATIONALE: Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. PATIENT CONCERNS AND DIAGNOSES: Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. INTERVENTIONS: Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. OUTCOMES: Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. LESSONS: Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.
format Online
Article
Text
id pubmed-6283193
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-62831932018-12-26 Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review Zheng, Shu-Yue Shen, Wen Peng, Yan-Mei Cui, Hui-Juan Duan, Hua Qiu, Yu-Qin Li, Qiang Zhang, Jing-Yi Sun, Chen-Yao Zhang, Xu Medicine (Baltimore) Research Article RATIONALE: Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. PATIENT CONCERNS AND DIAGNOSES: Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. INTERVENTIONS: Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. OUTCOMES: Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. LESSONS: Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research. Wolters Kluwer Health 2018-11-30 /pmc/articles/PMC6283193/ /pubmed/30508887 http://dx.doi.org/10.1097/MD.0000000000013088 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Zheng, Shu-Yue
Shen, Wen
Peng, Yan-Mei
Cui, Hui-Juan
Duan, Hua
Qiu, Yu-Qin
Li, Qiang
Zhang, Jing-Yi
Sun, Chen-Yao
Zhang, Xu
Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title_full Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title_fullStr Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title_full_unstemmed Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title_short Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
title_sort treatment of severe rash caused by crizotinib with both traditional chinese medicine and western medicine: two case reports and literature review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/
https://www.ncbi.nlm.nih.gov/pubmed/30508887
http://dx.doi.org/10.1097/MD.0000000000013088
work_keys_str_mv AT zhengshuyue treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT shenwen treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT pengyanmei treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT cuihuijuan treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT duanhua treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT qiuyuqin treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT liqiang treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT zhangjingyi treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT sunchenyao treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview
AT zhangxu treatmentofsevererashcausedbycrizotinibwithbothtraditionalchinesemedicineandwesternmedicinetwocasereportsandliteraturereview